raloxifene hydrochloride has been researched along with Osteoporotic Fractures in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.50) | 29.6817 |
| 2010's | 34 (85.00) | 24.3611 |
| 2020's | 5 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Salam, FS; Amer, MS; Basalious, EB; Elkasabgy, NA; Elkheshen, SA; Mahmoud, AA; Mostafa, AA | 1 |
| Davis, S; Gittoes, N; Hamilton, J; Martyn-St James, M; Selby, P; Simpson, EL; Wong, R | 1 |
| Abrahamsen, B; Cohen-Solal, M; Eastell, R; Guañabens, N; Langdahl, B; McKenna, MJ; Ralston, SH; van de Laarschot, DM; Zillikens, MC | 1 |
| Elgebaly, Z; Elliott, J; Naik-Panvelkar, P; Norman, S; Pollack, A; Seibel, MJ; Thistlethwaite, J; Weston, C | 1 |
| Davis, S; Gittoes, N; Goka, E; Hamilton, J; James, MM; Rawdin, A; Selby, P; Simpson, E; Wong, R | 1 |
| Fukunaga, M; Hagino, H; Miyazaki, T; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Sugimoto, T; Taguchi, A; Tanaka, S; Tsukiyama, M; Uemura, Y | 2 |
| Bannuru, RR; Buckley, L; Cannon, M; Fink, HA; Grossman, J; Guyatt, G; Hansen, KE; Humphrey, MB; Lane, NE; Magrey, M; McAlindon, T; Miller, AS; Miller, M; Morrison, L; Osani, M; Rao, M; Robinson, AB; Saha, S; Turgunbaev, M; Vaysbrot, E; Wolver, S | 1 |
| Baidya, S; Barron, R; Fujiwara, S; Hamaya, E; Miyauchi, A; Nicholls, RJ; Pinto, L; Takada, J; Weston, A | 1 |
| Balasubramanian, A; Cooper, C; Cummings, SR; Feudjo, MT; Guo, H; Sprafka, JM; Watts, NB; Yusuf, AA; Zhou, J | 1 |
| Black, DM; Cheung, AM; Eastell, R; Murad, MH; Rosen, CJ; Shoback, D | 1 |
| D'Amelio, P; Isaia, GC | 1 |
| Burge, R; Chu, BC; Curkendall, S; Diakun, DR; Foster, SA; Krege, JH; Shi, N; Stock, J | 1 |
| Chines, A; Kaufman, JM; Palacios, S; Silverman, S; Sutradhar, S | 1 |
| Lin, SJ; Lin, TC; Yang, CY; Yang, YH | 1 |
| Dalkin, AC; Pinkerton, JV; Thomas, S | 1 |
| Kanis, JA; Kim, K; Luo, X; Sutradhar, S; Svedbom, A | 1 |
| Kao Yang, YH; Lin, SJ; Lin, TC; Yang, CY | 1 |
| Silverman, S | 1 |
| Lee, CH; Lin, SJ; Lin, TC; Yang, CY; Yang, YH | 1 |
| Amugongo, SK; Dai, W; Dave, NK; Jia, J; Jiang, L; Lane, NE; Lay, YA; Li, CS; Olivera, D; Panganiban, B; Ritchie, RO; Walsh, D; Yao, W | 1 |
| Abdelazim, IA; Abdelrazak, KM; Al-Kadi, M; Faza, MA; Nusair, BM; Yehia, AH | 1 |
| Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V | 1 |
| Fogelman, I; Hampson, G; Ishtiaq, S | 1 |
| Reid, IR | 1 |
| Hirai, K; Inoue, T; Kanehara, H; Nagatoya, K; Nishimoto, K; Okada, S; Shibahara, N; Takahashi, T; Ueda, H; Ueno, N; Yasuda, H | 1 |
| Chen, YC; Cheng, TT; Lin, WC; Lui, CC; Su, FM | 1 |
| Chaki, O | 1 |
| Connolly, JG; Gagne, JJ | 1 |
| Isaka, Y; Sato, M; Sugihara, T; Ye, W | 1 |
| Fujiwara, S; Nakamura, M; Oda, E; Tanaka, S; Yamamoto, T | 1 |
| Bobula, J; Lips, P; van Schoor, NM; Yu, H | 1 |
| Brookhart, MA; Cadarette, SM; Katz, JN; Patrick, AR; Solomon, DH | 1 |
| Johansson, H; Kanis, JA; McCloskey, EV; Oden, A | 1 |
| D'Amelio, P; D'Amico, L; Ferracini, R; Isaia, GC; Patanè, S; Pescarmona, GP; Ravazzoli, M; Roato, I; Sassi, F; Tamone, C; Veneziano, L | 1 |
| Owens, G | 1 |
| Bauer, DC; Schousboe, JT | 1 |
| Suzuki, H; Takeuchi, Y | 1 |
| Goto, W; Hamaya, E; Iikuni, N; Miyauchi, A; Nihojima, S; Sowa, H; Taketsuna, M; Yokoyama, S | 1 |
| Ben Sedrine, W; Hiligsmann, M; Reginster, JY | 1 |
11 review(s) available for raloxifene hydrochloride and Osteoporotic Fractures
| Article | Year |
|---|---|
Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
Topics: Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Network Meta-Analysis; Osteoporotic Fractures; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome | 2020 |
Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.
Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Europe; Femoral Fractures; Humans; Osteoporotic Fractures; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Societies, Medical; Teriparatide | 2020 |
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Denosumab; Diphosphonates; Humans; Osteoporotic Fractures; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome | 2020 |
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Topics: Bone Density Conservation Agents; Calcium, Dietary; Consensus; Denosumab; Diphosphonates; Glucocorticoids; Humans; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Rheumatic Diseases; Rheumatology; Societies, Medical; Teriparatide; United States; Vitamin D | 2017 |
The use of raloxifene in osteoporosis treatment.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2013 |
Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options.
Topics: Absorptiometry, Photon; Bone Density Conservation Agents; Calcium, Dietary; Dietary Supplements; Diphosphonates; Drug Therapy, Combination; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Factors; Risk Reduction Behavior; Vitamin D | 2013 |
Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Topics: Adaptor Proteins, Signal Transducing; Anabolic Agents; Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Bone Remodeling; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Genetic Markers; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2015 |
A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Female; Humans; Incidence; Middle Aged; Osteoporotic Fractures; Placebos; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Treatment Outcome | 2010 |
Real-world challenges of treating osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Disease Management; Female; Hormone Replacement Therapy; Humans; Life Style; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Assessment | 2011 |
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Monitoring, Physiologic; Osteoporotic Fractures; Raloxifene Hydrochloride; Wound Healing; Zoledronic Acid | 2012 |
[Combination or sequential treatment using PTH and anti-resorption therapies].
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Teriparatide; Time Factors; Zoledronic Acid | 2012 |
5 trial(s) available for raloxifene hydrochloride and Osteoporotic Fractures
| Article | Year |
|---|---|
Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Japan; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Raloxifene Hydrochloride; Treatment Outcome | 2020 |
Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Incidence; Osteoporotic Fractures; Raloxifene Hydrochloride; Sample Size; Spinal Fractures | 2019 |
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Topics: Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Kaplan-Meier Estimate; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Spinal Fractures; Treatment Outcome | 2013 |
Cross-geographic region differences in quality of life in women with and without vertebral fracture.
Topics: Aged; Body Mass Index; Bone Density Conservation Agents; Epidemiologic Methods; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Psychometrics; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures | 2009 |
Teriparatide increases the maturation of circulating osteoblast precursors.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Calcium; Cell Differentiation; Drug Therapy, Combination; Female; Humans; Mesenchymal Stem Cells; Middle Aged; Osteoblasts; Osteocalcin; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Secondary Prevention; Teriparatide; Vitamin D | 2012 |
24 other study(ies) available for raloxifene hydrochloride and Osteoporotic Fractures
| Article | Year |
|---|---|
Long lasting in-situ forming implant loaded with raloxifene HCl: An injectable delivery system for treatment of bone injuries.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Implants; Drug Liberation; Humans; Injections, Intralesional; Male; Osteoporotic Fractures; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Raloxifene Hydrochloride; Rats; Surface Properties | 2019 |
Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
Topics: Aged; Aged, 80 and over; Attitude of Health Personnel; Australia; Bone Density Conservation Agents; Denosumab; Deprescriptions; Diphosphonates; Drug Substitution; Female; General Practice; General Practitioners; Humans; Longitudinal Studies; Male; Middle Aged; Norpregnenes; Osteoporosis; Osteoporotic Fractures; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; Thiophenes | 2020 |
Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Drug Utilization; Female; Humans; Incidence; Japan; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; Vitamin D | 2018 |
Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Spinal Fractures; Teriparatide; United States; Zoledronic Acid | 2018 |
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Topics: Absorptiometry, Photon; Accidental Falls; Bone Density Conservation Agents; Calcitonin; Calcium; Clinical Decision-Making; Denosumab; Diphosphonates; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Patient Preference; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Teriparatide; Vitamin D | 2019 |
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; United States; Women's Health | 2013 |
Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Case-Control Studies; Cohort Studies; Databases, Factual; Female; Follow-Up Studies; Humans; Incidence; Medication Adherence; Middle Aged; National Health Programs; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Secondary Prevention; Taiwan | 2013 |
Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
Topics: Aged; Algorithms; Bone Density Conservation Agents; Cost-Benefit Analysis; Decision Support Techniques; Dose-Response Relationship, Drug; Europe; Female; Health Care Costs; Health Services Research; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Raloxifene Hydrochloride; Risk Assessment; Sensitivity and Specificity | 2014 |
Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Calcitonin; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; Risk Assessment; Taiwan | 2014 |
Individualizing osteoporosis medications.
Topics: Absorptiometry, Photon; Administration, Intranasal; Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Female; Hip Fractures; Hot Flashes; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Precision Medicine; Raloxifene Hydrochloride; Risk Factors; Vitamin D | 2014 |
Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Female; Humans; Incidence; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; Risk; Taiwan; Venous Thromboembolism | 2014 |
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Femur; Hormone Replacement Therapy; Lumbar Vertebrae; Osteoporosis; Osteoporotic Fractures; Ovariectomy; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Weight-Bearing; X-Ray Microtomography | 2014 |
Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Case-Control Studies; Female; Humans; Kuwait; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride | 2014 |
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Female; Humans; Isoenzymes; Kidney Failure, Chronic; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Renal Dialysis; Tartrate-Resistant Acid Phosphatase | 2015 |
Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Middle Aged; Mortality; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Spinal Fractures; Vertebroplasty | 2015 |
[Selective estrogen receptor modulators (SERMs)].
Topics: Bone Density; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators | 2015 |
Comparison of Calipers for Matching on the Disease Risk Score.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Computer Simulation; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Ezetimibe; Female; Gastrointestinal Hemorrhage; Humans; Male; Medicare; Models, Theoretical; Monte Carlo Method; Odds Ratio; Osteoporotic Fractures; Prognosis; Propensity Score; Raloxifene Hydrochloride; Risk Assessment; Simvastatin; United States | 2016 |
Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Comorbidity; Diabetes Mellitus, Type 2; Female; Health Care Costs; Humans; Incidence; Japan; Middle Aged; Osteoporosis; Osteoporotic Fractures; Patient Acceptance of Health Care; Prevalence; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2016 |
Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.
Topics: Aged; Alendronate; Asian People; Bone Density Conservation Agents; Databases, Factual; Female; Hospitals; Humans; Incidence; Japan; Kaplan-Meier Estimate; Middle Aged; Osteoporotic Fractures; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risk | 2018 |
Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Female; Frail Elderly; Hip Fractures; Humans; Humerus; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Compliance; Pennsylvania; Radius Fractures; Raloxifene Hydrochloride; Ulna Fractures | 2011 |
Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance.
Topics: Aged; Asian People; Bone Density; Collagen Type I; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptides; Product Surveillance, Postmarketing; Raloxifene Hydrochloride | 2012 |
Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Incidence; Indoles; Models, Economic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Placebos; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome | 2013 |